SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

APONVIE

HRTX·HERON THERAPEUTICS, INC. /DE/
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since March 2023.
Why 4/10
APONVIE is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst is the closing of the CorMedix asset acquisition (expected Q1 2027), which is an M&A event, not a drug-specific binary catalyst. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Actionable Insight NEUTRAL

APONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.

Price Chart

Loading chart...

Executive Summary

APONVIE (aprepitant injectable emulsion) is an FDA-approved intravenous treatment for postoperative nausea and vomiting (PONV), developed by Heron Therapeutics (HRTX). Approved in September 2022 and commercially launched in March 2023, it is the first and only IV formulation of an NK1 receptor antagonist for PONV, delivered as a single 30-second injection. APONVIE revenue grew 49.3% YoY in Q3 2026, but on November 9, 2026, Heron announced it would sell substantially all assets -- including APONVIE -- to CorMedix Therapeutics (CRMD) for approximately $223M upfront plus earn-outs, with the deal expected to close in Q1 2027. For Heron shareholders, APONVIE's future economics are now tied to the CorMedix transaction rather than standalone commercial execution.

How It Works

APONVIE is an intravenous (IV) injectable emulsion of aprepitant, which blocks the neurokinin-1 (NK1) receptor in the brain that triggers nausea and vomiting. It is given as a single 30-second IV injection before surgery and provides 48 hours of protection against postoperative nausea and vomiting (PONV). Unlike oral anti-nausea pills, the IV formulation works quickly and is suitable for patients who cannot take oral medications after surgery.

Trial Status

APONVIE was FDA-approved on September 16, 2022, based on clinical trials demonstrating efficacy for prevention of postoperative nausea and vomiting. It was commercially launched in the U.S. in March 2023 and has since been included in the Fifth Consensus Guidelines for PONV management (December 2025).

The Two-Sided Case

▲ Bull Case4
APONVIE is the first and only FDA-approved IV formulation of a substance P/NK1 receptor antagonist for postoperative nausea and vomiting (PONV), a large addressable market of ~36 million annual U.S. procedures.
APONVIE revenue grew 49.3% YoY in Q3 2026, showing strong commercial momentum and market adoption.
APONVIE was included in the Fifth Consensus Guidelines for PONV management (December 2025), which should support continued adoption by hospital formularies.
The CorMedix acquisition values the four-product portfolio at ~$223M upfront plus earn-outs, and CorMedix expects the deal to be immediately accretive to earnings and free cash flow.
▼ Bear Case4
APONVIE faces competition from oral aprepitant (Emend) and other NK1 antagonists, as well as from generic antiemetics used in the hospital setting.
Heron's overall Q3 2026 revenue declined 7.8% YoY to $35.3M, and the company reported a net loss, indicating the broader business was under pressure before the asset sale.
The CorMedix asset sale (expected Q1 2027) means Heron shareholders will no longer directly benefit from APONVIE's future revenue growth; the upside is capped at the deal consideration.
Analyst consensus on HRTX is mixed with 4 holds, 1 sell, and 2 strong sells; the mean price target of $7 implies massive upside from the ~$0.37 stock price but reflects pre-deal expectations.

Upcoming Catalysts

  • Closing of CorMedix asset acquisition, expected Q1 2027 (the deal was announced November 9, 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

HERON THERAPEUTICS, INC. /DE/ DEFA14A HRTX ·Originating report

Sources · 7

Hover a chip for the title
1 prnewswire.com2 fiercepharma.com3 empr.com4 markets.businessinsider.com5 rttnews.com6 nasdaq.com7 sec.gov